OSTEOGROW
Novel Bone Morphogenetic Protein-6 Biocompatible Carrier Device for Bone Regeneration
| Coordinatore | "SVEUCILISTE U ZAGREBU, MEDICINSKI FAKULTET"
Organization address
address: SALATA 3 contact info |
| Nazionalità Coordinatore | Croatia [HR] |
| Sito del progetto | http://osteogrow.eu/ |
| Totale costo | 7˙384˙746 € |
| EC contributo | 5˙683˙089 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2016-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
"SVEUCILISTE U ZAGREBU, MEDICINSKI FAKULTET"
Organization address
address: SALATA 3 contact info |
HR (ZAGREB) | coordinator | 598˙613.00 |
| 2 |
GENERA ISTRAZIVANJA DRUSTVO S OGRANICENOM ODGOVORNOSCU ZA PROIZVODNJU BIOTEHNOLOSKIH PROIZVODA
Organization address
address: SVETONEDJELJSKA 2 contact info |
HR (KALINOVICA) | participant | 1˙474˙486.80 |
| 3 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 599˙400.00 |
| 4 |
LINKOPINGS UNIVERSITET
Organization address
address: CAMPUS VALLA contact info |
SE (LINKOPING) | participant | 459˙800.00 |
| 5 |
EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Organization address
address: Science Park 1, Stuhlsatzenhausweg 69 contact info |
DE (SAARBRUECKEN) | participant | 456˙125.00 |
| 6 |
MEDITOX S.R.O
Organization address
address: POD ZAMKEM 279 contact info |
CZ (KONAROVICE) | participant | 404˙659.50 |
| 7 |
KLINICKI BOLNICKI CENTAR SESTRE MILOSRDNICE USTANOVA
Organization address
address: VINOGRADSKA CESTA 29 contact info |
HR (ZAGREB) | participant | 402˙000.00 |
| 8 |
PAUL REGULATORY SERVICES LIMITED
Organization address
address: FISHER HILL WAY 15 contact info |
UK (CARDIFF) | participant | 374˙625.00 |
| 9 |
KLINICKI CENTAR UNIVERZITETA U SARAJEVU
Organization address
address: BOLNICKA 25 contact info |
BA (SARAJEVO) | participant | 360˙000.00 |
| 10 |
SGS VITROLOGY LIMITED
Organization address
address: SOUTH AVENUE 5 CLYDEBANK contact info |
UK (GLASCOW) | participant | 353˙340.00 |
| 11 |
SMART-MEDICO DOO
Organization address
address: ZUPANOVA 5 contact info |
HR (ZAGREB) | participant | 200˙040.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Goals: We propose a regenerative medicine clinical trial of the therapeutic system OSTEOGROW for regenerating bone through harnessing a novel bone device to accelerate and enhance bone repair. The osteogenic device is composed of an autologous carrier and a biologically active recombinant human protein offering a therapeutic solution in bone regeneration superior to currently available options. The autologous carrier is a whole blood-derived coagulum device (WBCD) from the peripheral blood of a patient, which will act as an endogenous biocompatible material causing significantly less inflammatory reactions than currently used bone devices. The bone inducing molecule is the recombinant human bone morphogenetic protein 6 (BMP6) which binds to WBCD and is more potent than other BMPs in stimulating bone formation in preclinical animal models. The consortium members will scale-up the production of BMP6 from an already developed working cell bank to enter clinical trials on bone regeneration. The bone diseases we will treat locally with OSTEOGROW are acute radius fractures and recalcitrant non-unions of the tibia. These conditions are widespread and highly debilitating diseases for which such therapy holds great promise. Workflow: Preliminary pre-clinical data are already available, and clinical grade (GMP) BMP6 will be available before the beginning of the project to perform toxicology studies and to determine the final formulation of OSTEOGROW. Clinical trials will start within 18 months from the start of the project funding. Business strategy: SMEs Genera Research and BioTest will develop and validate the BMP6 production in their facilities. Consortium members from Medical University of Vienna, Sarajevo University Clinical Centre, Linkoping University Faculty of Health Sciences, Zagreb University Trauma Clinic, SMART Medico and Paul Regulatory Services will perform, monitor and coordinate clinical trials. OSTEOGROW will find a wide use in human and veterinary medicine.'
Introduzione (Teaser)
Bone fractures provoke a particularly painful and lengthy healing process, which applies mainly to elderly patients. Current treatment options are associated with inflammation and other undesirable side-effects.